Cargando…

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer

Trastuzumab is an effective treatment for patients with metastatic breast cancer (MBC) that overexpresses HER-2. A high incidence of brain metastases (BM) has been noted in patients receiving trastuzumab. A retrospective chart review was conducted of 100 patients commencing trastuzumab for metastati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clayton, A J, Danson, S, Jolly, S, Ryder, W D J, Burt, P A, Stewart, A L, Wilkinson, P M, Welch, R S, Magee, B, Wilson, G, Howell, A, Wardley, A M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2004
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364775/ https://www.ncbi.nlm.nih.gov/pubmed/15266327 http://dx.doi.org/10.1038/sj.bjc.6601970

Ejemplares similares

53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB)
por: Lin, Nancy, et al.
Publicado: (2020)

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
por: Earl, H.M., et al.
Publicado: (2021)

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring
por: Jones, A L, et al.
Publicado: (2009)

Trastuzumab-associated cardiac events in the Persephone trial
por: Earl, Helena M, et al.
Publicado: (2016)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
por: Wu, Scott A, et al.
Publicado: (2023)

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
por: Swain, S. M., et al.
Publicado: (2014)

Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
por: Kabraji, Sheheryar, et al.
Publicado: (2023)

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
por: Wardley, Andrew, et al.
Publicado: (2021)

Incidence of central nervous system metastases in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with trastuzumab: A meta-analysis
por: Bai, Xue, et al.
Publicado: (2021)

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
por: Antonarelli, G., et al.
Publicado: (2023)

Effect of Central Nervous System Metastases on Treatment Discontinuation and Survival in Older Women Receiving Trastuzumab for Metastatic Breast Cancer
por: Danese, Mark D., et al.
Publicado: (2012)

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
por: Sutherland, S, et al.
Publicado: (2010)

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
por: Jerusalem, Guy, et al.
Publicado: (2022)

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
por: Ferraro, Emanuela, et al.
Publicado: (2022)

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
por: Lin, Nancy U., et al.
Publicado: (2020)

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
por: Mills, Matthew N., et al.
Publicado: (2021)

Complete Radiologic Response of Bulky Cerebral Metastases From Newly Diagnosed HER2-Positive Breast Cancer to Upfront Trastuzumab-Based Chemotherapy
por: Brungs, Daniel, et al.
Publicado: (2013)

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
por: Lu, Nu T., et al.
Publicado: (2015)

Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer
por: Terrell-Hall, Tori B., et al.
Publicado: (2017)

Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras
por: Karam, Irene, et al.
Publicado: (2013)

Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases
por: Jacobson, Anne
Publicado: (2022)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
por: Sanglier, Thibaut, et al.
Publicado: (2023)

Cerebral metastases of cutaneous melanoma.
por: Gupta, G., et al.
Publicado: (1997)

Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series
por: Stravodimou, Athina, et al.
Publicado: (2014)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Bisphosphonates and bone metastases.
por: Morton, A. R., et al.
Publicado: (1988)

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration
por: Wardley, A, et al.
Publicado: (2005)

(89)Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors
por: Chang, Albert J., et al.
Publicado: (2012)

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
por: Harder, J, et al.
Publicado: (2012)

Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report
por: Baudon, C., et al.
Publicado: (2016)

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
por: Lim, Bora, et al.
Publicado: (2019)

New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
por: Rose, Jeffrey S, et al.
Publicado: (2011)

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group
por: Mackey, J.R., et al.
Publicado: (2008)

Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
por: Dai, Wei Fang, et al.
Publicado: (2022)

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results
por: Hiller, Louise, et al.
Publicado: (2018)

Advanced magnetic resonance imaging biomarkers of cerebral metastases
por: Mills, S.J., et al.
Publicado: (2012)

Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases
por: Page, David B., et al.
Publicado: (2022)

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
por: Al Rabadi, Luai S., et al.
Publicado: (2021)

HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review
por: Chen, Min-long, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o9r4490amtol9dnsctmad08lfh